Decreased SARS-CoV-2 viral load following vaccination
Open accessPreprint — published as 10.1038/s41591-021-01316-7 · Paper page
Abstract
Beyond their substantial protection of individual vaccinees, it is hoped that the COVID-19 vaccines would reduce viral load in breakthrough infections thereby further suppress onward transmission. Here, analyzing positive SARS-CoV-2 test results following inoculation with the BNT162b2 mRNA vaccine, we find that the viral load is reduced 4-fold for infections occurring 12-28 days after the first dose of vaccine. These reduced viral loads hint to lower infectiousness, further contributing to vaccine impact on virus spread.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Early post-implementation analyses suggest mRNA vaccines reduce asymptomatic infection incidence and nasopharyngeal viral load in people infected despite vaccination.
“Some early post-implementation analyses have suggested that the mRNA vaccines also reduce the incidence of asymptomatic infection and the nasopharyngeal viral load in individuals who become infected despite the vaccination93,107, but it is yet unclear how this translates to risk of transmission.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [107]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · see citing works
Temporal dynamics in viral shedding and transmissibility of COVID-19
He, X., Lau, E. H. Y., Wu, P., Deng, X., Wang, J., Hao, X., Lau, Y. C., Wong, J. Y., Guan, Y., Tan, X., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0869-5 · Cited by 4,242 · see citing works
A guide to vaccinology: from basic principles to new developments
Pollard, A. J., & Bijker, E. M. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00479-7 · Cited by 1,593 · see citing works
Rethinking Covid-19 Test Sensitivity — A Strategy for Containment
Mina, M. J., Parker, R., & Larremore, D. B. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2025631 · Cited by 715 · see citing works
SARS-CoV-2 viral load predicts COVID-19 mortality
Pujadas, E., Chaudhry, F. F., McBride, R. B., Richter, F., Zhao, S., Wajnberg, A., Nadkarni, G. N., Glicksberg, B. S., Houldsworth, J., & Cordon‐Cardo, C. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30354-4 · Cited by 534 · see citing works
Evaluation of COVID-19 RT-qPCR Test in Multi sample Pools
Yelin, I., Aharony, N., Tamar, E. S., Argoetti, A., Messer, E., Berenbaum, D., Shafran, E., Kuzli, A., Gandali, N., Shkedi, O., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa531 · Cited by 450 · see citing works
Self-citationUnderstanding COVID-19 vaccine efficacy
Lipsitch, M., & Dean, N. E. (2020) · Science · doi:10.1126/science.abe5938 · Cited by 232 · see citing works
Chodick, G., Tene, L., Patalon, T., Gazit, S., Ben‐Tov, A., Cohen, D., & Muhsen, K. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.15985 · Cited by 185 · see citing works
Self-citationÇevik, M., Marcus, J. L., Buckee, C. O., & Smith, T. C. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1442 · Cited by 141 · see citing works
SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn
Connors, M., Graham, B. S., Lane, H. C., & Fauci, A. S. (2021) · Annals of Internal Medicine · doi:10.7326/m21-0111 · Cited by 69 · see citing works
SARS-CoV-2 Vaccination — An Ounce (Actually, Much Less) of Prevention
Rubin, E. J., & Longo, D. L. (2020) · New England Journal of Medicine · doi:10.1056/nejme2034717 · Cited by 60 · see citing works
Publisher Correction: A guide to vaccinology: from basic principles to new developments
Pollard, A. J., & Bijker, E. M. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-020-00497-5 · Cited by 46 · see citing works
Indirect benefits are a crucial consideration when evaluating SARS-CoV-2 vaccine candidates
Gallagher, M., Sieben, A. J., Nelson, K., Kraay, A. N. M., Orenstein, W. A., Lopman, B. A., Handel, A., & Koelle, K. (2020) · Nature Medicine · doi:10.1038/s41591-020-01172-x · Cited by 44 · see citing works
Levine-Tiefenbrun, M., Yelin, I., Uriel, H., Kuint, J., Schreiber, L., Herzel, E., Katz, R., Ben‐Tov, A., Gazit, S., Patalon, T., et al. (2021) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2021.10.010 · Cited by 18 · see citing works
Self-citation
Flagged first, then by citations
2 of the 16 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Chodcik, G. et al. The effectiveness of the first dose of BNT162 b 2 vaccine in reducing SARS-CoV-2 infection 13-24 days after immunization: real-world evidence. medRxiv 2021.01.27.21250612 (2021).
- Levine-Tiefenbrun, M. et al. Association of COVID-19 RT-qPCR test false-negative rate with patient age, sex and time since diagnosis. medRxiv (2020).
Cited by
Sorted by citations
Drug delivery systems for RNA therapeutics
Paunovska, K., Loughrey, D., & Dahlman, J. E. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-021-00439-4 · Cited by 1,349 · see citing works
Tregoning, J. S., Flight, K. E., Higham, S. L., Wang, Z., & Pierce, B. F. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00592-1 · Cited by 1,110 · see citing works
Fiolet, T., Kherabi, Y., MacDonald, C.-J., Ghosn, J., & Peiffer-Smadja, N. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.10.005 · Cited by 911 · see citing works
Singanayagam, A., Hakki, S., Dunning, J. W., Madon, K. J., Crone, M. A., Koycheva, A., Derqui, N., Barnett, J. L., Whitfield, M. G., Varro, R., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00648-4 · Cited by 745 · see citing works
Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus
Raman, B., Bluemke, D. A., Lüscher, T. F., & Neubauer, S. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac031 · Cited by 673 · see citing works
Immunological mechanisms of vaccine-induced protection against COVID-19 in humans
Sadarangani, M., Marchant, A., & Kollmann, T. R. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00578-z · Cited by 560 · see citing works
Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines
Thompson, M. G., Burgess, J. L., Naleway, A. L., Tyner, H. L., Yoon, S. K., Meece, J. K., Olsho, L. E. W., Caban-Martinez, A. J., Fowlkes, A. L., Lutrick, K., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107058 · Cited by 469 · see citing works
Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants
Eyre, D. W., Taylor, D., Purver, M., Chapman, D., Fowler, T., Pouwels, K. B., Walker, A. S., & Peto, T. E. A. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2116597 · Cited by 464 · see citing works
Kustin, T., Harel, N., Finkel, U., Perchik, S., Harari, S., Tahor, M., Caspi, I., Levy, R., Leshchinsky, M., Ken Dror, S., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01413-7 · Cited by 373 · see citing works
Effect of Vaccination on Household Transmission of SARS-CoV-2 in England
Harris, R., Hall, J., Zaidi, A., Andrews, N. J., Dunbar, J. K., & Dabrera, G. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2107717 · Cited by 355 · see citing works
Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273
Steensels, D., Pierlet, N., Penders, J., Mesotten, D., & Heylen, L. (2021) · JAMA · doi:10.1001/jama.2021.15125 · Cited by 351 · see citing works
Chia, P. Y., Ong, S. W. X., Chiew, C. J., Ang, L. W., Chavatte, J., Mak, T. M., Cui, L., Kalimuddin, S., Chia, W. N., Tan, C. W., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.11.010 · Cited by 323 · see citing works
Household transmission of SARS-CoV-2 Omicron variant of concern subvariants BA.1 and BA.2 in Denmark
Lyngse, F. P., Kirkeby, C., Denwood, M. J., Christiansen, L. E., Mølbak, K., Møller, C. H., Skov, R. L., Krause, T. G., Rasmussen, M., Sieber, R. N., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33498-0 · Cited by 300 · see citing works
Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors
Shroff, R. T., Chalasani, P., Wei, R., Pennington, D., Quirk, G., Schoenle, M. V., Peyton, K. L., Uhrlaub, J. L., Ripperger, T. J., Jergović, M., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01542-z · Cited by 233 · see citing works
Levine-Tiefenbrun, M., Yelin, I., Alapi, H., Katz, R., Herzel, E., Kuint, J., Chodick, G., Gazit, S., Patalon, T., & Kishony, R. (2021) · Nature Medicine · doi:10.1038/s41591-021-01575-4 · Cited by 222 · see citing works
Self-citationLapuente, D., Fuchs, J., Willar, J., Antão, A. V., Eberlein, V., Uhlig, N., Issmail, L., Schmidt, A. P., Oltmanns, F., Peter, A. S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27063-4 · Cited by 213 · see citing works
Shrotri, M., Krutikov, M., Palmer, T., Giddings, R., Azmi, B., Subbarao, S., Fuller, C., Irwin-Singer, A., Davies, D., Tut, G., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00289-9 · Cited by 180 · see citing works
The Effectiveness of the Two-Dose BNT162b2 Vaccine: Analysis of Real-World Data
Chodick, G., Tene, L., Rotem, R. S., Patalon, T., Gazit, S., Ben-Tov, A., Weil, C., Goldshtein, I., Twig, G., Cohen, D., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab438 · Cited by 176 · see citing works
Self-citationIn vivo kinetics of SARS-CoV-2 infection and its relationship with a person’s infectiousness
Ke, R., Zitzmann, C., Ho, D. D., Ribeiro, R. M., & Perelson, A. S. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2111477118 · Cited by 169 · see citing works
Drug delivery systems for CRISPR-based genome editors
Madigan, V. J., Zhang, F., & Dahlman, J. E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00762-x · Cited by 180 · see citing works
Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity
Hagin, D., Freund, T., Navon, M., Halperin, T., Adir, D., Marom, R., Levi, I., Benor, S., Alcalay, Y., & Freund, N. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.05.029 · Cited by 176 · see citing works
COVID-19 vaccines and decreased transmission of SARS-CoV-2
Vitiello, A., Ferrara, F., Troiano, V., & Porta, R. L. (2021) · Inflammopharmacology · doi:10.1007/s10787-021-00847-2 · Cited by 159 · see citing works
Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel
Prunas, O., Warren, J. L., Crawford, F. W., Gazit, S., Patalon, T., Weinberger, D. M., & Pitzer, V. E. (2022) · Science · doi:10.1126/science.abl4292 · Cited by 153 · see citing works
Self-citationCombining spike- and nucleocapsid-based vaccines improves distal control of SARS-CoV-2
Dangi, T., Class, J., Palacio, N. M., Richner, J. M., & Penaloza‐MacMaster, P. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109664 · Cited by 145 · see citing works
Quantifying the relationship between SARS-CoV-2 viral load and infectiousness
Marc, A., Kerioui, M., Blanquart, F., Bertrand, J., Mitjà, J., Corbacho‐Monné, M., Marks, M., & Guedj, J. (2021) · eLife · doi:10.7554/elife.69302 · Cited by 146 · see citing works
The use of RNA-based treatments in the field of cancer immunotherapy
Chehelgerdi, M., & Chehelgerdi, M. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01807-w · Cited by 146 · see citing works
Patel, M. K., Bergeri, I., Bresee, J., Cowling, B. J., Crowcroft, N. S., Fahmy, K., Hirve, S. S., Kang, G., Katz, M. A., Lanata, C. F., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.05.099 · Cited by 143 · see citing works
Rosen, B., Waitzberg, R., Israeli, A., Hartal, M., & Davidovitch, N. (2021) · Israel Journal of Health Policy Research · doi:10.1186/s13584-021-00481-x · Cited by 148 · see citing works
Bayart, J., Douxfils, J., Gillot, C., David, C., Mullier, F., Elsen, M., Eucher, C., Eeckhoudt, S. V., Roy, T., Gérin, V., et al. (2021) · Vaccines · doi:10.3390/vaccines9101092 · Cited by 136 · see citing works
Higdon, M. M., Wahl, B., Jones, C. B., Rosen, J. G., Truelove, S., Baidya, A., Nande, A., ShamaeiZadeh, P. A., Walter, K. K., Feikin, D. R., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac138 · Cited by 125 · see citing works
Reactance revisited: Consequences of mandatory and scarce vaccination in the case of COVID‐19
Sprengholz, P., Betsch, C., & BOHM, R. M. (2021) · Applied Psychology Health and Well-Being · doi:10.1111/aphw.12285 · Cited by 131 · see citing works
Antibody Responses to SARS-CoV-2 mRNA Vaccines Are Detectable in Saliva
Ketas, T. J., Chaturbhuj, D. N., Portillo, V. M. C., Francomano, E., Golden, E. B., Chandrasekhar, S., Debnath, G., Diaz-Tapia, R., Yasmeen, A., Kramer, K. D., et al. (2021) · Pathogens and Immunity · doi:10.20411/pai.v6i1.441 · Cited by 129 · see citing works
Langel, S. N., Johnson, S., Martinez, C. I., Tedjakusuma, S. N., Peinovich, N., Dora, E. G., Kuehl, P. J., Irshad, H., Barrett, E. G., Werts, A. D., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn6868 · Cited by 121 · see citing works
Should children be vaccinated against COVID-19?
Zimmermann, P., Pittet, L. F., Finn, A. H. R., Pollard, A. J., & Curtis, N. C. (2021) · Archives of Disease in Childhood · doi:10.1136/archdischild-2021-323040 · Cited by 125 · see citing works
Haas, E. J., McLaughlin, J. M., Khan, F. L., Angulo, F. J., Anis, E., Lipsitch, M., Singer, S. R., Mircus, G., Brooks, N., Smaja, M., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00566-1 · Cited by 125 · see citing works
Bertels, X., Demeyer, P., den Bogaert, S. V., Boogaerts, T., van Nuijs, A. L. N., Delputte, P., & Lahousse, L. (2022) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2022.153290 · Cited by 120 · see citing works
Concerns about SARS-CoV-2 evolution should not hold back efforts to expand vaccination
Cobey, S. E., Larremore, D. B., Grad, Y. H., & Lipsitch, M. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00544-9 · Cited by 118 · see citing works
Long Covid: where we stand and challenges ahead
Mantovani, A., Morrone, M. C., Patrono, C., Santoro, M., Schiaffino, S., Remuzzi, G., Bussolati, G., On behalf of the Covid-19 Commission of the Accademia Nazionale dei Lincei, Cappuccinelli, P., Fitzgerald, G., et al. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-022-01052-6 · Cited by 116 · see citing works
Decreased infectivity following BNT162b2 vaccination: A prospective cohort study in Israel
Regev-Yochay, G., Amit, S., Bergwerk, M., Lipsitch, M., Leshem, E., Kahn, R., Lustig, Y., Cohen, C., Doolman, R., Ziv, A., et al. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100150 · Cited by 111 · see citing works
Morvan, M., Jacomo, A. L., Souque, C., Wade, M. J., Hoffmann, T., Pouwels, K. B., Lilley, C. J., Singer, A. C., Porter, J., Evens, N. P., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31753-y · Cited by 100 · see citing works
Community-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals
Milman, O., Yelin, I., Aharony, N., Katz, R., Herzel, E., Ben‐Tov, A., Kuint, J., Gazit, S., Chodick, G., Patalon, T., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01407-5 · Cited by 109 · see citing works
Self-citationCabore, J. W., Karamagi, H. C., Kipruto, H. K., Mungatu, J. K., Asamani, J. A., Droti, B., Titi-ofei, R., Seydi, A. B. W., Kidane, S. N., Balde, T., et al. (2022) · The Lancet Global Health · doi:10.1016/s2214-109x(22)00233-9 · Cited by 108 · see citing works
Schwartz, D. A., Mulkey, S. B., & Roberts, D. J. (2022) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2022.10.001 · Cited by 103 · see citing works
Prevention of host-to-host transmission by SARS-CoV-2 vaccines
Mostaghimi, D., Valdez, C. N., Larson, H. T., Kalinich, C. C., & Iwasaki, A. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00472-2 · Cited by 94 · see citing works
Hasan, T., Beardsley, J., Marais, B. J., Nguyen, T. A., & Fox, G. J. (2021) · Vaccines · doi:10.3390/vaccines9040326 · Cited by 94 · see citing works
Amodio, D., Ruggiero, A., Sgrulletti, M., Pighi, C., Cotugno, N., Medri, C., Rocchi, F., Colagrossi, L., Russo, C., Zaffina, S., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.727850 · Cited by 93 · see citing works
Salvagno, G. L., Henry, B. M., Piazza, G. D., Pighi, L., NITTO, S. D., Bragantini, D., Gianfilippi, G. L., & Lippi, G. (2021) · Diagnostics · doi:10.3390/diagnostics11050832 · Cited by 90 · see citing works
The success of SARS-CoV-2 vaccines and challenges ahead
Subbarao, K. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.06.016 · Cited by 90 · see citing works
The impact of SARS-CoV-2 vaccination on Alpha and Delta variant transmissionPreprint
Eyre, D. W., Taylor, D., Purver, M. B., Chapman, D., Fowler, T., Pouwels, K. B., Walker, A. S., & Peto, T. (2021) · medRxiv · doi:10.1101/2021.09.28.21264260 · Cited by 88 · see citing works
Abu-Raddad, L. J., Chemaitelly, H. S., Ayoub, H. H., Tang, P., Coyle, P. V., Hasan, M. R., Yassine, H. M., Benslimane, F. M., Al-Khatib, H. A., Kanaani, Z. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28199-7 · Cited by 79 · see citing works
Model-driven mitigation measures for reopening schools during the COVID-19 pandemic
McGee, R. S., Homburger, J. R., Williams, H., Bergstrom, C. T., & Zhou, A. Y. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2108909118 · Cited by 78 · see citing works
Covid-19: variants and vaccination
Darby, A. C., & Hiscox, J. A. (2021) · BMJ · doi:10.1136/bmj.n771 · Cited by 78 · see citing works
Zollner, A., Watschinger, C., Rössler, A., Farcet, M. R., Penner, A., Böhm, V., Zollner-Kiechl, S., Stampfel, G., Hintenberger, R., Tilg, H., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103539 · Cited by 75 · see citing works
Improved control of SARS-CoV-2 by treatment with a nucleocapsid-specific monoclonal antibody
Dangi, T., Sanchez, S., Class, J., Richner, M., Visvabharathy, L., Chung, Y. R., Bentley, K., Stanton, R. J., Koralnik, I. J., Richner, J. M., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci162282 · Cited by 69 · see citing works
Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges
Amanatidou, E., Gkiouliava, A., Pella, E., Serafidi, M., Tsilingiris, D., Vallianou, N. G., Karampela, Ι., & Dalamaga, Μ. (2022) · Metabolism Open · doi:10.1016/j.metop.2022.100180 · Cited by 76 · see citing works
Long-Term Autoimmune Inflammatory Rheumatic Outcomes of COVID-19
Kim, M. S., Lee, H., Lee, S. W., Kwon, R., Rhee, S. Y., Lee, J. A., Koyanagi, A., Smith, L., Fond, G. B., Boyer, L., et al. (2024) · Annals of Internal Medicine · doi:10.7326/m23-1831 · Cited by 75 · see citing works
Salo, J., Hägg, M., Kortelainen, M., Leino, T. M., Saxell, T., Siikanen, M., & Sääksvuori, L. (2022) · Nature Communications · doi:10.1038/s41467-022-28825-4 · Cited by 73 · see citing works
mRNA vaccines: Past, present, future
Karam, M., & Daoud, G. (2022) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2022.05.003 · Cited by 74 · see citing works
Mortari, E. P., Russo, C., Vinci, M. R., Terreri, S., Salinas, A. F., Piccioni, L., Alteri, C., Colagrossi, L., Coltella, L., Ranno, S., et al. (2021) · Cells · doi:10.3390/cells10102541 · Cited by 70 · see citing works
Bauer, S., Contreras, S., Dehning, J., Linden, M., Iftekhar, E. N., Mohr, S., Olivera‐Nappa, Á., & Priesemann, V. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009288 · Cited by 70 · see citing works
Ponsford, M., Ward, T., Stoneham, S. M., Dallimore, C. M., Sham, D., Osman, K., Barry, S. M., Jolles, S. R. A., Humphreys, I. R., & Farewell, D. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.744696 · Cited by 68 · see citing works
Six months of COVID vaccines: what 1.7 billion doses have taught scientists
Ledford, H. K. (2021) · Nature · doi:10.1038/d41586-021-01505-x · Cited by 67 · see citing works
Marfella, R., Sardu, C., D’Onofrio, N., Prattichizzo, F., Scisciola, L., Messina, V., Grotta, R. L., Balestrieri, M. L., Maggi, P., Claudio Napoli, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30068-2 · Cited by 68 · see citing works
Rovida, F., Cassaniti, I., Paolucci, S., Percivalle, E., Sarasini, A., Piralla, A., Giardina, F., Sammartino, J. C., Ferrari, A., Bergami, F., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26154-6 · Cited by 61 · see citing works
Can COVID vaccines stop transmission? Scientists race to find answers
Mallapaty, S. (2021) · Nature · doi:10.1038/d41586-021-00450-z · Cited by 67 · see citing works
Hayes, E. K., Sweeney, C. L., Anderson, L. E., Li, B., Erjavec, G. B., Gouthro, M., Krkošek, W. H., Stoddart, A. K., & Gagnon, G. A. (2021) · Environmental Science Water Research & Technology · doi:10.1039/d1ew00207d · Cited by 65 · see citing works
COVID-19 vaccine acceptance among high-risk populations in Uganda
Bongomin, F., Olum, R., Biraro, I. A., Nakwagala, F. N., Hassan, K. H., Nassozi, D. R., Kaddumukasa, M., Byakika‐Kibwika, P., Kiguli, S., & Kirenga, B. (2021) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361211024376 · Cited by 60 · see citing works
Goldberg, Y., Mandel, M., Woodbridge, Y., Fluss, R., Novikov, I., Yaari, R., Ziv, A., Freedman, L. S., & Huppert, A. (2022) · American Journal of Epidemiology · doi:10.1093/aje/kwac060 · Cited by 64 · see citing works
Waning of SARS-CoV-2 booster viral-load reduction effectiveness
Levine-Tiefenbrun, M., Yelin, I., Alapi, H., Herzel, E., Kuint, J., Chodick, G., Gazit, S., Patalon, T., & Kishony, R. (2022) · Nature Communications · doi:10.1038/s41467-022-28936-y · Cited by 63 · see citing works
Self-citationVaccine rollout strategies: The case for vaccinating essential workers early
Mulberry, N., Tupper, P. F., Kirwin, E. M., McCabe, C. J., & Colijn, C. (2021) · PLOS Global Public Health · doi:10.1371/journal.pgph.0000020 · Cited by 62 · see citing works
Banho, C. Á., Sacchetto, L., Campos, G. R. F., Bittar, C., Possebon, F. S., Ullmann, L. S., Marques, B. D. C., da Silva, G. C. D., Moraes, M. M., Parra, M. C. P., et al. (2022) · Communications Medicine · doi:10.1038/s43856-022-00108-5 · Cited by 63 · see citing works
Can a combination of vaccination and face mask wearing contain the COVID‐19 pandemic?
Brüssow, H., & Zuber, S. (2021) · Microbial Biotechnology · doi:10.1111/1751-7915.13997 · Cited by 61 · see citing works
Postvaccination COVID‐19 infection is associated with reduced mortality in patients with cirrhosis
John, B. V., Deng, Y., Schwartz, K. B., Taddei, T. H., Kaplan, D. E., Martin, P. B., Chao, H., & Dahman, B. A. (2022) · Hepatology · doi:10.1002/hep.32337 · Cited by 56 · see citing works
Efficacy of COVID-19 vaccines: From clinical trials to real life
Deplanque, D., & Launay, O. (2021) · Therapies · doi:10.1016/j.therap.2021.05.004 · Cited by 57 · see citing works
Epidemics, the Ising-model and percolation theory: A comprehensive review focused on Covid-19
Mello, I. F., Squillante, L., Gomes, G. O., Seridonio, A. C. F., & Souza, M. D. (2021) · Physica A Statistical Mechanics and its Applications · doi:10.1016/j.physa.2021.125963 · Cited by 56 · see citing works
Rénia, L., Goh, Y. S., Rouers, A., Bert, N. L., Chia, W. N., Chavatte, J., Fong, S., Chang, Z. W., Zhuo, N. Z., Tay, M. Z., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32312-1 · Cited by 58 · see citing works
Delivery Routes for COVID-19 Vaccines
Park, J. H., & Lee, H. K. (2021) · Vaccines · doi:10.3390/vaccines9050524 · Cited by 53 · see citing works
Hanson, K. E., Altayar, O., Caliendo, A. M., Arias, C. A. D., Englund, J. A., Hayden, M. K., Lee, M. J., Loeb, M. B., Patel, R., Alayli, A. E., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab557 · Cited by 55 · see citing works
A Systematic Review of the Sex and Gender Reporting in COVID-19 Clinical Trials
Heidari, S., Palmer-Ross, A., & Goodman, T. (2021) · Vaccines · doi:10.3390/vaccines9111322 · Cited by 54 · see citing works
Signals of hope: gauging the impact of a rapid national vaccination campaign
Shilo, S., Rossman, H., & Segal, E. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00531-0 · Cited by 53 · see citing works
Woodbridge, Y., Amit, S., Huppert, A., & Kopelman, N. M. (2022) · Nature Communications · doi:10.1038/s41467-022-33096-0 · Cited by 53 · see citing works
Gaballa, S. A., Shimizu, T., Ando, H., Takata, H., Emam, S. E., Ramadan, E., Naguib, Y. W., Mady, F. M., Khaled, K. A., & Ishida, T. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2023.11.001 · Cited by 58 · see citing works
Transmission of SARS-CoV-2 variant B.1.1.7 among vaccinated health care workers
Ιωάννου, Π., Karakonstantis, S., Astrinaki, E., Saplamidou, S., Vitsaxaki, E., Hamilos, G., Sourvinos, G., & Kofteridis, D. P. (2021) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2021.1945139 · Cited by 52 · see citing works
Monge, S., Olmedo, C., Alejos, B., Lapeña, M. F., Sierra, M. J., Limia, A., & COVID-19 registries study group (2021) · Emerging infectious diseases · doi:10.3201/eid2710.211184 · Cited by 49 · see citing works
Sun, K., Tempia, S., Kleynhans, J., von Gottberg, A., McMorrow, M. L., Wolter, N., Bhiman, J. N., Moyes, J., du Plessis, M., Carrim, M., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abo7081 · Cited by 52 · see citing works
Booster Vaccination to Reduce SARS-CoV-2 Transmission and Infection
Wald, A. (2022) · JAMA · doi:10.1001/jama.2021.23726 · Cited by 52 · see citing works
Kahnbach, L., Lehr, D., Brandenburger, J., Mallwitz, T., Jent, S., Hannibal, S., Funk, B., & Janneck, M. (2021) · Journal of Medical Internet Research · doi:10.2196/27989 · Cited by 51 · see citing works
Bošnjak, B., Odak, I., Barros‐Martins, J., Sandrock, I., Hammerschmidt, S. I., Permanyer, M., Patzer, G. E., Georgiev, H., Jauregui, R. G., Tscherne, A., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.772240 · Cited by 49 · see citing works
Siedner, M. J., Boucau, J., Gilbert, R. F., Uddin, R., Luu, J., Haneuse, S., Vyas, T. D., Reynolds, Z., Iyer, S. L., Chamberlin, G. C., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.155483 · Cited by 49 · see citing works
Efficacy Estimates for Various COVID-19 Vaccines: What we Know from the Literature and ReportsPreprint
Shapiro, J., Dean, N. E., Madewell, Z. J., Yang, Y., Halloran, M. E., & Longini, I. M. (2021) · medRxiv · doi:10.1101/2021.05.20.21257461 · Cited by 46 · see citing works
Xu, K., Dai, L., & Gao, G. F. (2021) · International Immunology · doi:10.1093/intimm/dxab061 · Cited by 48 · see citing works
Krüger, L. J., Tanuri, A., Lindner, A. K., Gaeddert, M., Köppel, L., Tobian, F., Brümmer, L. E., Klein, J. A. F., Lainati, F., Schnitzler, P., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103774 · Cited by 48 · see citing works
Long-Term Safety of Rituximab (Risks of Viral and Opportunistic Infections)
Varley, C. D., & Winthrop, K. L. (2021) · Current Rheumatology Reports · doi:10.1007/s11926-021-01037-3 · Cited by 47 · see citing works
Revisiting COVID-19 policies: 10 evidence-based recommendations for where to go from here
Halperin, D. T., Hearst, N., Hodgins, S., Bailey, R. C., Klausner, J. D., Jackson, H., Wamai, R. G., Ladapo, J. A., Over, M., Baral, S., et al. (2021) · BMC Public Health · doi:10.1186/s12889-021-12082-z · Cited by 45 · see citing works
Efficacy of mRNA, adenoviral vector, and perfusion protein COVID-19 vaccines
Zinatizadeh, M. R., Zarandi, P. K., Zinatizadeh, M., Yousefi, M. H., Amani, J., & Rezaei, N. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112527 · Cited by 48 · see citing works
Hegazy, N., Cowan, A., D’Aoust, P. M., Mercier, É., Towhid, S. T., Jia, J., Wan, S., Zhang, Z., Kabir, M. P., Fang, W., et al. (2022) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2022.158458 · Cited by 43 · see citing works
Servellita, V., Morris, M. K., Sotomayor-González, A., Gliwa, A. S., Torres, E., Brazer, N., Zhou, A. Y., Hernandez, K., Sankaran, M., Wang, B., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-021-01041-4 · Cited by 46 · see citing works
Divalent siRNAs are bioavailable in the lung and efficiently block SARS-CoV-2 infection
Hariharan, V. N., Shin, M., Chang, C., O’Reilly, D., Biscans, A., Yamada, K., Guo, Z., Somasundaran, M., Tang, Q., Monopoli, K. R., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2219523120 · Cited by 48 · see citing works
Richterman, A. G., Meyerowitz, E. A., & Çevik, M. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab259 · Cited by 44 · see citing works
Batra, K., Sharma, M., Dai, C., & Khubchandani, J. (2022) · Vaccines · doi:10.3390/vaccines10050758 · Cited by 44 · see citing works
- Authors
- Levine-Tiefenbrun, M., Yelin, I., Katz, R., Herzel, E., Golan, Z., Schreiber, L., Wolf, T., Nadler, V., Ben-Tov, A., Kuint, J., Gazit, S., Patalon, T., Chodick, G., & Kishony, R.
- Affiliations
- Technion – Israel Institute of Technology (IL)
- Maccabi Healthcare Services (IL)
- Tel Aviv University (IL)
- Corresponding author
- Yelin, Idan
- Kishony, Roy
- ORCID
- Venue
- Nature Medicine
- Publisher
- openRxiv
- Published
- 2021-02-08
- Volume
- 27
- Issue
- 5
- Pages
- 790-792
- ISSN
- 1078-8956 (ISSN-L)
- OpenAlex
- W3150351745
- Cited by
- 514
- References
- 16
- Citations by year
- 2026: 4 · 2025: 12 · 2024: 19 · 2023: 67 · 2022: 166 · 2021: 242 · 2020: 4
- FWCI
- 39.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Nature Medicine (publishedVersion)
- medRxiv (acceptedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Israel Science Foundation (3633/19)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- SARS-CoV-2, COVID-19 pandemic, BNT162b2, mRNA vaccines, breakthrough infection, viral load, infectiousness, transmission reduction, vaccine effectiveness, real-world data
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Vaccination, Viral Load, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
